Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This proposed Phase II trial will investigate the combination of irinotecan and carboplatin
followed by sunitinib in the first-line treatment of patients with extensive-stage SCLC.